Keeping Track: A Little Bit Of (Nearly) Everything
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials
The Pink Sheet takes a closer look at recent clinical announcements showing how rare disease therapy sponsors are already increasingly reliant on natural history studies to guide drug development.
Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.